Literatur
-
1
Horneff G.
Biologics for treatment of juvenile idiopathic arthritis. Consensus statement of the 7th Worlitzer Expertengesprache 2004 for the German Arbeitsgemeinschaft Kinder- und Jugendrheumatologie.
Z Rheumatol.
2006;
65
152
-
2
McCann L J, Woo P.
Biologic therapies in juvenile idiopathic arthritis: why and for whom?.
Acta Reumatol Port..
2007;
32
15
-
3
Romero J R.
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Pediatr Infect Dis J.
2003;
22
S46
-
4
Simon T, Hero B, Faldum A. et al .
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.
J Clin Oncol.
2004;
22
3549
-
5
Ruperto N, Lovell D J, Cuttica R. et al .
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
Arthritis Rheum.
2007;
56
3096
-
6
Sobrin L, Kim E C, Christen W, Papadaki T, Letko E, Foster C S.
Infliximab therapy for the treatment of refractory ocular inflammatory disease.
Arch Ophthalmol.
2007;
125
895
-
7
Veres G, Baldassano R N, Mamula P.
Infliximab therapy in children and adolescents with inflammatory bowel disease.
Drugs.
2007;
67
1703
-
8
Culic S, Armanda V, Kuljis D, Kuzmic I, Pranic-Kragic A, Jankovic S.
Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocytepredominant Hodgkin lymphoma in an 10-year-old girl.
Pediatr Hematol Oncol.
2006;
23
661
-
9
Motto D G, Williams J A, Boxer L A.
Rituximab for refractory childhood autoimmune hemolytic anemia.
Isr Med Assoc J.
2002;
4
1006
-
10
Bennett C M, Rogers Z R, Kinnamon D D. et al .
Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
Blood.
2006;
107
2639
-
11
Marks S D, Patey S, Brogan P A. et al .
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
Arthritis Rheum.
2005;
52
3168
-
12
Vazquez-Cobian L B, Flynn T, Lehman T J.
Adalimumab therapy for childhood uveitis.
J Pediatr.
2006;
149
572
-
13
Verbsky J W, White A J.
Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis.
J Rheumatol.
2004;
31
2071
-
14
Boschan C, Witt O, Lohse P, Foeldvari I, Zappel H, Schweigerer L.
Neonatalonset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment.
Am J Med Genet A.
2006;
140
883
-
15
Leslie K S, Lachmann H J, Bruning E. et al .
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.
Arch Dermatol.
2006;
142
1591
-
16
Spada M, Petz W, Bertani A. et al .
Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression.
Am J Transplant.
2006;
6
1913
-
17
Grenda R, Watson A, Vondrak K. et al .
A prospective, randomized, multicenter trial of tacrolimusbased therapy with or without basiliximab in pediatric renal transplantation.
Am J Transplant.
2006;
6
1666
-
18
Lovell D J, Giannini E H, Reiff A. et al .
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
N Engl J Med.
2000;
342
763
-
19
Lovell D J, Reiff A, Jones O Y. et al .
Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Arthritis Rheum.
2006;
54
1987
-
20
Henrickson M, Reiff A.
Prolonged efficacy of etanercept in refractory enthesitisrelated arthritis.
J Rheumatol.
2004;
31
2055
-
21
Sanchez Carazo J L, Mahiques Santos L, Oliver Martinez V.
Safety of etanercept in psoriasis: a critical review.
Drug Saf.
2006;
29
675
-
22
Hull K M, Drewe E, Aksentijevich I. et al .
The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
Medicine (Baltimore).
2002;
81
349
-
23
Schmeling H, Horneff G.
Etanercept and uveitis in patients with juvenile idiopathic arthritis.
Rheumatology (Oxford).
2005;
44
1008
-
24
Horneff G, Schmeling H, Biedermann T. et al .
The German etanercept registry for treatment of juvenile idiopathic arthritis.
Ann Rheum Dis.
2004;
63
1638
-
25
Lebwohl M, Christophers E, Langley R, Ortonne J P, Roberts J, Griffiths C E.
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Arch Dermatol.
2003;
139
719
-
26
Baert F, de Vos M, Louis E, Vermeire S.
Immunogenicity of infliximab: how to handle the problem?.
Acta Gastroenterol Belg.
2007;
70
163
-
27
Biancone L, Calabrese E, Petruzziello C, Pallone F.
Treatment with biologic therapies and the risk of cancer in patients with IBD.
Nat Clin Pract Gastroenterol Hepatol.
2007;
4
78
Priv. Doz. Dr. Johannes-Peter Haas
Zentrum für Kinder- und Jugendmedizin
Ernst Moritz Arndt Universität Greifswald
Soldmannstr. 15
17475 Greifswald
Telefon: 03834/866301
eMail: jphaas@uni-greifswald.de
